Recent Posts

• Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces Details of LACRIFILL® Canalicular Gel Poster Presentation At SECO 2025
• Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Continues Its Introduction of LACRIFILL^® Canalicular Gel, a Novel Therapy for Dry Eye, During American Academy of Ophthalmology (AAO) 2024
• Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL^® Canalicular Gel, a Novel Therapy for Dry Eye
• Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL^® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
• Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Appoints Renowned Oculoplastic Surgeon, John P. Fezza, MD to Its Medical Advisory Board